CHF Solutions, Inc. Announces Pricing of $18.0 Million Underwritten Public Offering

Posted on

EDEN PRAIRIE, Minn., Nov. 22, 2017 (GLOBE NEWSWIRE) — CHF Solutions, Inc. (NASDAQ:CHFS) announced today the pricing of an underwritten public offering of Series F convertible preferred stock, together with warrants, for gross proceeds of $18.0 million, prior to deducting underwriting discounts and commissions and offering expenses payable by CHF Solutions. The Series F preferred stock is convertible into shares of the […]

Read More

CHF Solutions, Inc. Announces Ultrafiltration Meta-Analysis Highlighting Significant Reduction in Heart Failure Readmissions at 90 Days

Posted on

EDEN PRAIRIE, Minn., Nov. 07, 2017 (GLOBE NEWSWIRE) — CHF Solutions, Inc. (NASDAQ:CHFS) announced today that the Heart Failure Reviews released a comprehensive meta-analysis1 evaluating the role of ultrafiltration (UF) in reducing hospital readmissions in acute decompensated heart failure (ADHF) patients.  The positive results of this meta-analysis, which included CHF Solutions’ Aquadex FlewFlow® system, are consistent with previous publications that demonstrate […]

Read More

CHF Solutions’ Aquadex FlexFlow® Ultrafiltration System Receives FDA IDE Approval for Clinical Study for Pediatric Use

Posted on

EDEN PRAIRIE, Minn., June 29, 2017 (GLOBE NEWSWIRE) — CHF Solutions, Inc., (fka Sunshine Heart, Inc.) (NASDAQ:CHFS) announced today that researchers in the Stanford University School of Medicine’s Department of Pediatrics have received FDA Investigational Device Exemption (IDE) approval to conduct a clinical study to evaluate the safety and effectiveness of CHF Solutions’ Aquadex FlexFlow Aquapheresis System for diuretic-resistant fluid overload in children […]

Read More

CHF Solutions, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Posted on

EDEN PRAIRIE, Minn., June 06, 2017 (GLOBE NEWSWIRE) — CHF Solutions, Inc. (NASDAQ:CHFS), today announced that on May 25, 2017, the independent directors approved two equity awards under CHF Solution’s New-Hire Equity Incentive Plan, as material inducements to two individuals entering into employment with the Company. The equity awards were approved in accordance with NASDAQ Listing Rule 5635(c)(4), which also […]

Read More

CHF Solutions’ Aquadex Flexflow® Ultrafiltration System Featured in the May 2017 Journal of The American College of Cardiology Review of Ultrafiltration as a Promising Treatment for Fluid Overload Associated with Heart Failure

Posted on

EDEN PRAIRIE, Minn., June 05, 2017 (GLOBE NEWSWIRE) — CHF Solutions, Inc., (fka Sunshine Heart, Inc.) (NASDAQ:CHFS) announced today that clinical trials using its Aquadex FlexFlow® Ultrafiltration System are featured in the May 2017 Journal of the American College of Cardiology (JACC) Treatment Review Paper, Extracorporeal Ultrafiltration for Fluid Overload in Heart Failure – Current Status and Prospects for Further Research.  The retrospective […]

Read More